Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 4/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126564 | 0.91 | PIK3CB (0.55) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL21980342 | 0.91 | PIK3CD (0.54) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL153714 | 0.88 | PIK3CD (0.54) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL31628325 | 0.88 | PIK3CD (0.54) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL153713 | 0.88 | PIK3CD (0.54) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL19656225 | 0.88 | PIK3CD (0.54) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL12885795 | 0.86 | PIK3CD (0.55) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL11901315 | 0.84 | NPC1 (0.51) | PIK3CBPIK3CG | |
| SCHEMBL15260579 | 0.82 | PIK3CG (0.57) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA | |
| SCHEMBL11901795 | 0.82 | NPC1 (0.49) | PIK3CBPIK3CDPIK3R1PIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143902-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | GILEAD CALISTOGA LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143902-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | GILEAD CALISTOGA LLC (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013082540-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | GILEAD CALISTOGA LLC (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143902-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | TP53, KRAS, MKI67 | PIK3CB 681/4885PIK3CD 670/4885PIK3R1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.